Stock Report

Download full stock data and analysis for free Last Updated: 02-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Curis Lifesciences Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: CURIS

₹137.50

up-down-arrow ₹0.95 (0.70%)

As on 01-Sep-2026IST

Market cap

info icon

₹111 Cr

Revenue (TTM)

info icon

₹49 Cr

P/E Ratio

info icon

16.1

P/B Ratio

info icon

2.3

Div. Yield

info icon

0 %

Edit peer-selector-edit
Curis Lifesciences Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Market cap (₹ Cr)
 111 35,015 29,555 17,723 15,518
Revenue (₹ Cr)
 49 9,683 2,372 2,590 1,108
Net Profit (₹ Cr)
 6.11 1,018.97 497.77 603.02 270.18
Net Margin (%)
 12.30 10.47 20.72 22.63 23.29
RoE (%)
 55.25 21.30 28.49 19.61 14.45
Price to Earnings
 16.07 34.62 59.37 29.39 56.35
Price-To-Book
 2.35 6.69 14.62 5.09 7.48

Income Statement (₹ Cr)

Curis Lifesciences Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Operating Revenue arrow
49.13 7,896.00 1,476.84 2,386.88 1,200.09
Total Income arrow
49.65 7,968.78 1,497.35 2,421.45 1,244.53
Total Expenditure arrow
39.58 6,427.14 1,153.58 1,704.30 693.24
EBITDA arrow
9.55 1,468.85 323.26 682.58 506.84
Depreciation arrow
0.67 384.13 65.55 60.61 54.37
EBIT arrow
8.87 1,084.73 257.71 621.98 452.47
Interest arrow
1.12 175.78 8.30 2.41 1.04
Other Income arrow
0.51 72.79 20.51 34.57 44.45
Exceptional Items arrow
-- -10.38 76.40 -- --
Profit before Tax arrow
8.27 971.35 346.33 654.13 494.55
Provision for Tax arrow
2.16 263.88 86.22 168.50 122.91
Profit after Tax arrow
6.11 707.47 260.11 485.63 371.64

Liabilities (₹ Cr)

Curis Lifesciences Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Shareholder's Funds arrow
16.23 4,446.19 1,524.81 2,817.37 1,812.72
Minority Interest arrow
-- 195.37 -- -- --
Non-Current Liabilities arrow
8.73 811.91 189.39 466.05 37.47
Current Liabilities arrow
17.58 2,668.27 465.69 470.16 184.06
Total Liabilities arrow
42.53 8,121.73 2,179.88 3,753.59 2,034.25

Assets (₹ Cr)

Curis Lifesciences Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Non-Current Assets arrow
11.24 3,565.87 1,040.38 1,418.43 899.01
Current Assets arrow
31.29 4,555.86 1,139.50 2,335.16 1,135.24
Total Assets arrow
42.53 8,121.73 2,179.88 3,753.59 2,034.25
Total Debt* arrow
15.62 731.70 136.01 0.00 0.38
Net Current Assets arrow
13.72 1,887.59 673.81 1,865.00 951.18
Contingent Liabilities arrow
0.21 393.94 8.97 4.82 3.91

Cashflow (₹ Cr)

Curis Lifesciences Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Cash From Operating Activities arrow
-1.76 851.71 317.40 391.52 244.52
Cash Flow from Investing Activities arrow
-0.02 -94.00 -298.16 -615.65 -159.99
Cash from Financing Activities arrow
1.67 -813.96 24.96 -6.23 -98.77
Net Cash Inflow / Outflow arrow
-0.11 -56.25 44.21 -230.35 -14.24

Ratios

Profitability Ratios

 Curis Lifesciences Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
ROCE (%) arrow
34.25 22.49 23.45 25.50 29.62
ROE (%) arrow
55.25 19.19 18.54 18.94 22.26
ROA (%) arrow
15.98 8.94 12.97 13.34 19.90
EBIT Margin (%) arrow
20.48 19.52 23.28 30.05 45.94
Net Margin (%) arrow
12.30 8.88 17.37 20.06 29.86
Cash Profit Margin (%) arrow
13.80 13.61 22.05 22.79 35.50

Growth Ratios

 Curis Lifesciences Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Revenue Growth (%) arrow
38.18 18.59 -5.24 4.54 18.01
EBIT Growth (%) arrow
14.91 19.81 -27.65 4.50 18.31
Net Profit Growth (%) arrow
25.44 34.10 -13.32 3.13 20.62
EPS Growth (%) arrow
16.26 30.75 -13.32 3.12 20.62
Book Value Growth (%) arrow
176.31 50.94 18.89 20.94 18.74

Valuation Ratios

 Curis Lifesciences Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Price / Earnings arrow
0.00 29.84 59.57 27.24 47.19
Price / Book Value arrow
0.00 4.58 10.17 4.71 9.67
Dividend Yield (%) arrow
-- 0.28 0.10 0.46 0.64
EV/EBITDA arrow
2.11 13.55 44.72 18.35 31.81
Market Cap (₹ Cr) arrow
0.00 20,327.45 15,494.53 13,228.83 17,537.35

Solvency Ratios

 Curis Lifesciences Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debt to Equity arrow
0.96 0.17 0.09 0.00 0.00
Short term debt to equity ratio arrow
0.44 0.11 -- -- 0.00
Current Ratio arrow
1.78 1.71 2.45 4.97 6.17
Quick Ratio arrow
0.73 0.98 1.62 3.53 4.87
Interest Coverage arrow
8.41 6.53 42.74 271.97 475.76

Operating Efficiency Ratios

 Curis Lifesciences Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debtors to sales (%) arrow
15.31 25.36 21.38 40.63 43.47
Asset Turnover arrow
1.29 1.01 0.74 0.66 0.64
Receivable days arrow
65.45 87.83 85.17 132.12 132.49
Inventory Days arrow
101.63 78.64 90.97 102.08 68.07
Payable days arrow
121.29 174.97 137.94 133.54 123.94
Cash Conversion Cycle arrow
45.79 -8.50 38.21 100.66 76.63
loading...
loading...
loading...